drug · small molecule
etavopivat
Phase 3updated 3mo agoby Novo Nordisk AS🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.
indications
indications
Sickle Cell Disease
targets
Pyruvate kinase PKLR
all catalysts(0)
nothing on the calendar yet
Trials studying etavopivat
- phase2A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
- phase3A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- phase2Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
- phase3A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
- phase3A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- phase1A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants
- phase1A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants
- phase2A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
News(3)
- Biotechs bring big launches and pharma rivalries into Q2 earnings periodWith the second quarter earnings period underway, BioSpace examines five biotechs with meaningful catalysts that analysts and investors are watching.biospace · 22d ago
- Agios axes next-gen sickle cell candidate after it fails to best Novo’s assetAgios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the…biospace · 1mo ago
- Agios says adios to sickle cell program over lackluster phase 2 dataA phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase activator has failed to support continued development in sickle cell disease, leading the company to ax an indication for t…fiercebiotech · 1mo ago
Data sources
last refreshed 42m ago
Found something off?
comments(0)
5-min edit window · permanent after that